5B). that, together, maintain the health of the proteome [5]. There is a growing appreciation that this proteostasis network includes many untapped drug targets, a perspective enforced by recent clinical successes with proteasome inhibitors [6C8] and autophagy inducers Rabbit polyclonal to ADI1 [9]. However, other possible targets in the network, including Hsp70, warmth shock protein 90 (Hsp90) and proteins involved in the unfolded protein response (UPR), have confirmed more difficult to safely inhibit [10C12]. Another issue is usually that these challenging targets are inexorably linked to each other as part of the broader proteostasis network, often making it hard to anticipate the impact of perturbing a specific node [13]. In this review, we focus on Hsp70 as a model for this type of target complexity and we spotlight how recent examples of allosteric Hsp70 inhibition are illuminating both the challenges and opportunities. MULTI-DOMAIN ALLOSTERY AND DYNAMICS IN HSP70 Hsp70 is composed of an N-terminal, 45 kDa, nucleotide-binding domain name (NBD) and a C-terminal, 35 kDa, substrate-binding domain name (SBD). The NBD is usually divided into two lobes (I and II) that are further split into four subdomains (IA, IIA, IB, IIB). In turn, the SBD is usually comprised of a beta-sandwich domain name (SBD) that contains the substrate-binding cleft and an alpha-helical lid domain name (SBD) that regulates affinity for misfolded proteins (biochemical mechanisms (nucleotide hydrolysis) to cellular outcomes. In other words, the molecules discovered thus far might be considered tool compounds for learning about the structure-function associations in this system. This approach aims to produce definitions of Hsp70 function that are based on pharmacology, a strategy patterned after success in the study of GPCRs and ion channels Volitinib (Savolitinib, AZD-6094) [44]. MULTIPLE ALLOSTERIC BINDING SITES ON HSP70 In the cell, Hsp70 might be best considered the core of a dynamic, multi-protein sub-network composed of co-chaperones, nucleotides and substrates. Dramatic allosteric transitions and changes in both intra- and inter-molecular interactions accompany the motions of Hsp70 and these activities are powered by nucleotide turnover. In the face of this orchestrated series of motions, it is not surprising that numerous inhibitors of Hsp70 have been discovered [45C46] or that many of these inhibitors have non-degenerate binding sites [47C52]. In theory, Hsp70 is rich in possible allosteric regulatory sites and, as it transitions through an ATP hydrolysis cycle, these sites are expected to appear/disappear [16, 30]. In addition, binding to co-chaperones would be expected to hide some possible sites (when induced allostery discloses a previously buried site). Viewed this way, each Hsp70 conformer and each Hsp70 complex with its co-chaperones might be considered an independent drug target. In this review, we will focus on three of the classes of Hsp70 inhibitors, exemplified by MKT-077, VER-155008 and YK5 (Fig. 2). We will discuss how emerging evidence suggests that they each disrupt Hsp70 function through a complex, domino effect Volitinib (Savolitinib, AZD-6094) on allostery, dynamics and protein-protein interactions. We discuss how each of these inhibitors, because of their unique binding sites, might have both and effects on Hsp70 structure-function. A major theme (or speculation) is usually that each of these Hsp70 inhibitors, because of its unique properties, might be expected to have some similar, but also some dissimilar, effects in cells and animals. Thus, by better understanding the molecular mechanisms of an inhibitor, we might be able to better select the right tool for the job. It is worth noting that there have been many other inhibitors of Hsp70 reported [53C57]. To focus the discussion, we have selected three that have good evidence of Volitinib (Savolitinib, AZD-6094) selectivity and well-defined binding sites, while recent reviews cover the broader field [58C60]. Open in a separate windows Fig. 2 Three classes of Hsp70 inhibitors: MKT-077, VER-155008, and YK5. These molecules bind in three unique.